The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CAI | N/A | N/A | N/A | -9% |
| S&P | +13.59% | +79.97% | +12.46% | +16% |
No news articles found for Caris Life Sciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $216.83M | 113.4% |
| Gross Profit | $147.51M | 232.1% |
| Gross Margin | 68.03% | 24.3% |
| Market Cap | $8.51B | 0.0% |
| Market Cap / Employee | $4.81M | 0.0% |
| Employees | 1.8K | 0.0% |
| Net Income | $24.33M | 135.9% |
| EBITDA | $37.54M | 174.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $754.74M | 0.0% |
| Accounts Receivable | $26.70M | 0.0% |
| Inventory | 49.3 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $420.12M | 0.0% |
| Short Term Debt | $6.61M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -263.66% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $55.33M | 177.7% |
| Operating Free Cash Flow | $62.43M | 189.9% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Book | -2.86 | 18.77 | - | ||
| Price to Sales | 14.07 | 13.15 | - | ||
| Price to Tangible Book Value | -2.84 | 19.61 | - | ||
| Enterprise Value to EBITDA | -621.89 | 218.51 | - | ||
| Total Debt | $424.26M | $419.83M | $418.98M | $426.74M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
